MedTrace Logo

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT02207530 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2020-09-29

Study results available
· View outcomes & findings →

Summary

Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR

Conditions

  • Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

MEDI4736

MEDI4736 monotherapy

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Dan Paul Zandberg, MD · International Coordinating Investigator

  • Magdalena Wrona · Medical Scientist AstraZeneca [email protected]

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-23
Primary Completion
2016-09-26
Completion
2020-07-06

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • France
  • Georgia
  • Germany
  • Hungary
  • Israel
  • Malaysia
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02207530 on ClinicalTrials.gov